AU2012213244A1 - Diagnostic method - Google Patents

Diagnostic method Download PDF

Info

Publication number
AU2012213244A1
AU2012213244A1 AU2012213244A AU2012213244A AU2012213244A1 AU 2012213244 A1 AU2012213244 A1 AU 2012213244A1 AU 2012213244 A AU2012213244 A AU 2012213244A AU 2012213244 A AU2012213244 A AU 2012213244A AU 2012213244 A1 AU2012213244 A1 AU 2012213244A1
Authority
AU
Australia
Prior art keywords
level
sample
compound
determining
hepatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012213244A
Other languages
English (en)
Inventor
Shahid Aziz Khan
Mohammed I.F. Shariff
Simon D. TAYLOR-ROBINSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ip2ipo Innovations Ltd
Original Assignee
Imperial Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial Innovations Ltd filed Critical Imperial Innovations Ltd
Publication of AU2012213244A1 publication Critical patent/AU2012213244A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G01N33/57525—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G01N33/575—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/08—Hepato-biliairy disorders other than hepatitis
    • G01N2800/085—Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/17—Nitrogen containing
    • Y10T436/173845—Amine and quaternary ammonium
    • Y10T436/174614—Tertiary amine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/20—Oxygen containing
    • Y10T436/200833—Carbonyl, ether, aldehyde or ketone containing
    • Y10T436/201666—Carboxylic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2012213244A 2011-01-31 2012-01-31 Diagnostic method Abandoned AU2012213244A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1101667.2A GB201101667D0 (en) 2011-01-31 2011-01-31 Diagnostic method
GB1101667.2 2011-01-31
PCT/GB2012/000100 WO2012104585A2 (en) 2011-01-31 2012-01-31 Diagnostic method

Publications (1)

Publication Number Publication Date
AU2012213244A1 true AU2012213244A1 (en) 2013-09-05

Family

ID=43824891

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2012213244A Abandoned AU2012213244A1 (en) 2011-01-31 2012-01-31 Diagnostic method

Country Status (9)

Country Link
US (1) US20140134751A1 (cg-RX-API-DMAC7.html)
EP (1) EP2671077A2 (cg-RX-API-DMAC7.html)
JP (1) JP2014505254A (cg-RX-API-DMAC7.html)
KR (1) KR20140007414A (cg-RX-API-DMAC7.html)
CN (1) CN103430022A (cg-RX-API-DMAC7.html)
AP (1) AP2013007084A0 (cg-RX-API-DMAC7.html)
AU (1) AU2012213244A1 (cg-RX-API-DMAC7.html)
GB (1) GB201101667D0 (cg-RX-API-DMAC7.html)
WO (1) WO2012104585A2 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201307256D0 (en) * 2013-04-22 2013-05-29 Imp Innovations Ltd Diagnostic method
JP7230335B2 (ja) * 2018-04-02 2023-03-01 味の素株式会社 取得方法、算出方法、評価装置、算出装置、評価プログラム、算出プログラム、記録媒体、及び評価システム
CN111638324B (zh) * 2020-05-28 2023-08-11 长沙都正生物科技有限责任公司 一种冠心病诊断生物标记物组合及其应用
GB202102105D0 (en) * 2021-02-15 2021-03-31 Novabiotics Ltd Prognostic method
CN114414611B (zh) * 2022-01-25 2025-07-15 嘉兴大学 一种肝癌微血管侵犯鉴别模型的构建方法及肝癌微血管侵犯预测值的测试方法
WO2025008463A1 (en) 2023-07-06 2025-01-09 Numares Ag Use of a marker set for determining the risk of an individual to have hepatocellular carcinoma
KR102881746B1 (ko) * 2024-04-19 2025-11-06 주식회사 티엠에이오 인체내 트리메틸아민-n-옥사이드(tmao) 진단을 위한 키트 및 항체의 이용

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070015146A1 (en) * 2001-05-22 2007-01-18 Gene Logic, Inc. Molecular nephrotoxicology modeling
CN1197973C (zh) * 2001-12-27 2005-04-20 张抗 肝癌诊断、监护及肝硬化监护试剂盒
WO2005003285A1 (fr) * 2003-06-05 2005-01-13 Tijani Gharbi Systeme de mesure d'au moins une characteristique d'un tissu biologique et procede de fixation d'un tissu biologique sur un tel systeme de mesure
US7373256B2 (en) * 2005-04-19 2008-05-13 Nicholson Jeremy K Method for the identification of molecules and biomarkers using chemical, biochemical and biological data
CN101464271A (zh) * 2007-12-19 2009-06-24 苏州艾杰生物科技有限公司 甘氨酸诊断/测定试剂盒及甘氨酸的浓度测定方法

Also Published As

Publication number Publication date
WO2012104585A2 (en) 2012-08-09
JP2014505254A (ja) 2014-02-27
WO2012104585A3 (en) 2012-12-27
EP2671077A2 (en) 2013-12-11
KR20140007414A (ko) 2014-01-17
US20140134751A1 (en) 2014-05-15
AP2013007084A0 (en) 2013-08-31
GB201101667D0 (en) 2011-03-16
CN103430022A (zh) 2013-12-04

Similar Documents

Publication Publication Date Title
Dinges et al. Cancer metabolomic markers in urine: evidence, techniques and recommendations
Pérez-Rambla et al. Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia
Gowda et al. Metabolomics-based methods for early disease diagnostics
US20140134751A1 (en) Diagnostic method
Bu et al. Metabolomics: a revolution for novel cancer marker identification
Tian et al. Wang Y
AU2011260390A1 (en) Means and methods for diagnosing pancreatic cancer in a subject
Li et al. Nuclear Magnetic Resonance technique in tumor metabolism
US20110123976A1 (en) Biomarkers and identification methods for the early detection and recurrence prediction of breast cancer using NMR
Yi et al. Metabolomic identification of novel biomarkers of nasopharyngeal carcinoma
Levink et al. Longitudinal changes of serum protein N-Glycan levels for earlier detection of pancreatic cancer in high-risk individuals
Edgar et al. Low-field benchtop NMR spectroscopy as a potential non-stationary tool for point-of-care urinary metabolite tracking in diabetic conditions
WO2025123592A1 (zh) 用于诊断肺癌分期的代谢标志物的应用及试剂盒
Dasgupta et al. Discovery of novel metabolic signatures for early identification of women at risk of developing gestational hypertension
Peta et al. Input of serum haptoglobin fucosylation profile in the diagnosis of hepatocellular carcinoma in patients with non-cirrhotic liver disease
EP4414709A1 (en) Diagnostic biomarker for cancer and use thereof
US20160091494A1 (en) Diagnostic method for hepatic cancer
Azagra et al. Ammonium quantification in human plasma by proton nuclear magnetic resonance for staging of liver fibrosis in alcohol‐related liver disease and nonalcoholic fatty liver disease
Kumar et al. Serum metabolic disturbances associated with acute-on-chronic liver failure in patients with underlying alcoholic liver diseases: An elaborative NMR-based metabolomics study
Quartieri et al. Sample optimization for saliva 1H-NMR metabolic profiling
Kromke et al. Profiling human blood serum metabolites by nuclear magnetic resonance spectroscopy: a comprehensive tool for the evaluation of hemodialysis efficiency
Gautam et al. Metabolic dysregulation in amyotrophic lateral sclerosis: insights from 1H NMR-based metabolomics in a tertiary care center in India
Li et al. Serum metabolomic analysis of human upper urinary tract urothelial carcinoma
US9885719B2 (en) Composition comprising lysophosphatidylcholine and homocysteic acid for ovarian cancer diagnosis and method using the same
KR102344385B1 (ko) 간암 진단용 조성물 및 이를 포함하는 키트

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ TAYLOR-ROBINSON, SIMON D.; KHAN, SHAHID AZIZ AND SHARIFF, MOHAMMED I.F.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted